CHIA Kee Seng is Professor and Dean of Saw Swee Hock School of Public Health, National University of Singapore and Director, Centre for Molecular Epidemiology at the National University of Singapore. He is also an Adjunct Professor of Epidemiology at the Karolinska Institutet, Sweden.

Mr CHIA started his professional career as an occupational medicine specialist and is currently a member of the Workplace Safety and Health Council, chairs the Workplace Health Committee and is member of the WSH Institute Steering Committee.

His current research focus is in the molecular epidemiology of chronic diseases (cancer, cardiovascular disease, myopia, and diabetes mellitus) and its primary prevention, health informatics and workplace health.

Helen Chung leads research and development initiatives in the fields of medicine and health care, both in-house and through collaboration with academic research units. Her current focus areas include the impact of developments in the prevention, detection and treatment of cancer on longevity. She has a multi-disciplinary background connecting medical and actuarial fields with health policy. She worked in the UK National Health Service for 7 years, most recently in the Centre for Health Technology Evaluation at the National Institute for Health and Clinical Excellence (NICE), and formerly as hospital clinician. At NICE she applied research to the development of evidence-based guidance on the clinical and cost effective use of medical technologies (predominantly biologics and pharmaceuticals, but also including devices, diagnostics and surgical procedures). She has also 4 years of experience in actuarial work, in the development of health insurance products at Munich Re and in employee benefits consulting at Aon.

Ms Chung qualified in medicine from the University of London. Her undergraduate studies included an intercalated year focused on medical research methodology, particularly in molecular oncology. Her post-graduate studies were in Health Policy Planning and Finance at the London School of Economics and London School of Hygiene and Tropical Medicine. She is qualified as an Associate of the Institute of Actuaries.

David B. Matchar is the Professor of Medicine at Duke University and Inaugural Director of the Program in Health Services and Systems Research at the Duke-National University of Singapore Graduate Medical School.

For nearly 30 years, Professor Matchar has worked in academic clinical policy analysis and development, and clinical practice improvement. He focuses his research on the evaluation of clinical practice based on “best evidence,” and the implementation and evaluation of innovative strategies to promote practice change. He has worked in a wide range of clinical content areas, including cerebrovascular disease, women’s health issues, renal disease, Alzheimer’s disease, multiple sclerosis, migraine, and antithrombotic strategies.

His methodological work addresses the design of effectiveness studies, strategies for bridging the gap between analysts and policy makers, utilizing models to promote communication regarding complex clinical policy questions, and application of decision support systems to link evidence and community practice. He has been the principal investigator of the Stroke Prevention Patient Outcomes Research Team (PORT), a comprehensive seven-year project to evaluate the state of the science in stroke prevention and to implement strategies for practice improvement. He was also the principal investigator for a trial of anticoagulation services in managed care organizations, the Managing Anticoagulation Services Trial (MAST). Currently, he is principal investigator of a four-year implementation trial for practice improvement, the 28-city VA cooperative study #481, The Home International Normalized Ratio Study (THINRS).

In August 2009, Professor Matchar was awarded the prestigious STaR Investigator Award by the Singapore Ministry of Health's National Medical Research Council (NMRC) to establish a system modeling laboratory to evaluate clinical and public policy issues related to aging and disability in Singapore.

Christoph Nabholz is Head of Business Development at the Swiss Re Centre for Global Dialogue and additionally serves as Research & Development Manager to Swiss Re’s Life & Health Division.

As Head of Business Development he is responsible for the content of high-profile industry events held at the Centre for Global Dialogue, Swiss Re’s premiere conference facility. With his background in genetics he actively supports Swiss Re’s research on and development activities in medical trends and longevity.

Before joining the Centre, Mr Nabolz was Strategic Research Manager in Global Life & Health Underwriting and served as Swiss Re’s Global Genetics Consultant.

Prior to joining Swiss Re, he was a postdoctoral fellow in genomics and functional genetics with Prof. Tom Maniatis at Harvard University. He received a diploma in biochemistry from the University of Basel, Switzerland, and a Ph.D. with honours in molecular genetics from the University of Freiburg, Switzerland.

Mr John Schoonbee graduated from the University of Cape Town in 1995. He performed his internship at Groote Schuur Hospital. After some years in private medical practice he joined the corporate world which included working at a company that specialized in corporate sick leave management in its own right, as well as the link to future short and long term disability. Pension and insurance related disability assessments were also a key part of the work there, including redesigning state disability practices and assessment formats in some of the key government departments in South Africa.

Mr Schoonbee then started his own consulting company focusing on sick leave and disability consulting, and while there he began to work for  RGA in South Africa in 2005. He eventually became Chief Medical Officer and Head of Research for RGA South Africa, involved in many functions across the organization, including claims, underwriting, marketing, training and presentations to both clients and across the industry. He did product development and marketing work for RGA in Europe as well as South East Asia and Australia. Mr Schoonbee initiated and successfully completed the 2010 RGA Claims Survey, a first of its kind in the South African market, and in his research role he also spearheaded the beginning of an industry wide accidental experience analysis at RGA.

Mr Schoonbee was secretary of the Medical Underwriting Standing Committee of the South African industry body ASISA (Association of Saving and Investment of South Africa), and a key part of the team that organized the 2010 ICLAM meeting in Cape Town, where he also presented. Mr Schoonbee began working at Swiss Re in July 2011 as Chief Medical Officer for Continental Europe, Middle East, and Africa.